Clinical Trial Update: Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator [NA]

View source ↗

Summary

A terminated clinical trial evaluated whether response to infliximab or adalimumab could be regained with an immunomodulator in inflammatory bowel disease, incl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Inflammatory Bowel Disease
• Ulcerative Colitis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)
• Infliximab (infliximab)

Snippet

Sponsor: Indiana University | Conditions: Inflammatory Bowel Disease, Ulcerative Colitis | NA | Status: TERMINATED | Results posted: 2019-11-04